Actively Recruiting
The Effects of ECMO on the Pharmacokinetics of Hydromorphone
Led by Xiaobo Yang, MD · Updated on 2024-08-06
26
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.
CONDITIONS
Official Title
The Effects of ECMO on the Pharmacokinetics of Hydromorphone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 18 and 80
- Using hydromorphone for pain relief
- Using ECMO for more than 96 hours
You will not qualify if you...
- Allergic to hydromorphone
- Use of CRRT during ECMO
- Liver function Child-Pugh B, C grade
- Pregnancy
- Intestinal obstruction
- Refused to sign the informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wuhan Union Hospital
Wuhan, Hubei, China, 430022
Actively Recruiting
Research Team
Y
You Shang, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here